Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of California, Los Angeles | OTHER |
| University of California, Irvine | OTHER |
Not provided
Not provided
Not provided
Not provided
This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate two polypore mushrooms, Fomitopsis officinalis and Trametes versicolor (FoTv), to treat COVID-19-positive outpatients with mild-to-moderate symptoms assigned to self-quarantined and home management. The study aims to establish the safety and feasibility of the use of FoTv vs placebo in 66 total subjects.
Despite biomedical advances, medical intervention for COVID-19 is largely limited to vaccinations and supportive care during the later stages of disease. While antiviral, anti-inflammatory, and antimalarial options have been explored for later stages of disease, fewer studies have been conducted on medications to reduce the risk of outpatient cases progressing to severe disease. Therefore, it is important that we broaden the search to include agents outside of our usual pharmacopeia. Integrative Medicine offers several promising therapeutics that are available today and warrant investigation.
Some of the botanicals used for their possible immune modulating functions include polypore mushrooms. Among these, Turkey Tail (Trametes versicolor) has a long history of use for its immune supporting properties. An RCT examining the effects of Trametes versicolor in breast cancer patients detected increases in lymphocyte counts and natural killer cell functional activity (Torkelson et al, 2012 and Benson et al, 2019) both of which are key to host COVID-19 response. Further investigations into other relevant mushroom species demonstrated that Agarikon (Fomitopsis officinalis) can strongly induce an array of differential cytokine responses associated with both immune-activation and resolution of host defense- induced inflammatory reactions (unpublished). This homeostatic effect deserves attention for COVID-19 given the high mortality rate associated with cytokine storm.
This is a multi-center, randomized, double blind, placebo-controlled clinical trial to evaluate two polypore mushrooms, Fomitopsis officinalis and Trametes versicolor (FoTv), to treat COVID-19-positive outpatients with mild-to-moderate symptoms assigned to self-quarantined and home management. This study aims to establish the safety and feasibility of the use of FoTv vs placebo in 66 total subjects. Subsequent trials will evaluate Chinese herbal medicine as well as the efficacy of FoTv in a larger study population.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Mushrooms | Experimental | Fomitopsis officinalis and Trametes versicolor |
|
| Placebo | Placebo Comparator | Organic brown rice |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| FoTv | Drug | 8 capsules three times a day for 14 consecutive days. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Total Protein Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | 14 days |
| Albumin Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | 14 days |
| Alkaline Phosphatase Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | 14 days |
| AST Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | 14 days |
| ALT Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | 14 days |
| Bilirubin Normal to Abnormal Transition |
| Measure | Description | Time Frame |
|---|---|---|
| Total Bilirubin | comparison of the Total Bilirubin of baseline laboratory data with end-of-treatment labs | 14 days |
| Prothrombin Time | comparison of the prothrombin time of baseline laboratory data with end-of-treatment labs |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Any of the following symptoms which, according to the CDC, require hospitalization:
Current use of investigational agents to prevent or treat COVID-19
Known liver disease (ALT/AST >3x ULN or diagnosis of cirrhosis)
Known renal disease (eGFR < 60 ml/min) or acute nephritis.
Uncontrolled hypertension (SBP>140 or DBP>90 while on medications)
Pregnant or breastfeeding women
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Andrew Shubov, MD | University of California, Los Angeles | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California, Los Angeles | Los Angeles | California | 90095 | United States | ||
| University of California, San Diego |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Mushrooms | Fomitopsis officinalis and Trametes versicolor FoTv: 8 capsules three times a day for 14 consecutive days. |
| FG001 | Placebo | Organic brown rice FoTv: 8 capsules three times a day for 14 consecutive days. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Mushrooms | Fomitopsis officinalis and Trametes versicolor FoTv: 8 capsules three times a day for 14 consecutive days. |
| BG001 | Placebo | Organic brown rice FoTv: 8 capsules three times a day for 14 consecutive days. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Total Protein Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | All participants who were normal at baseline were also normal at day 14, so Chi-square statistic could not be computed. | Posted | Number | percentage of participants | 14 days |
|
14 days
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Mushrooms | Fomitopsis officinalis and Trametes versicolor FoTv: 8 capsules three times a day for 14 consecutive days. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| high blood pressure | Vascular disorders | Non-systematic Assessment | an individual with hypertension reported abnormal blood pressure on days 2-6 and 8-14 |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Gordon Saxe, M.D./Ph.D. | Krupp Center for Integrative Research, University of California San Diego | 6195435765 | gsaxe@health.ucsd.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Oct 13, 2021 | Aug 15, 2025 | Prot_SAP_003.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. |
| 14 days |
| Adj. EGFR Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | 14 days |
| Prothrombin Time Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | 14 days |
| APTT Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | 14 days |
| ESR Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | 14 days |
| CRP Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | 14 days |
| LDH Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | 14 days |
| 14 days |
| Aspartate Aminotransferase (AST) | Comparison of the aspartate transaminase of baseline laboratory data with end-of-treatment labs | 14 days |
| Alanine Transaminase (ALT) | The safety of the study medication will also assessed by a comparison of the alanine transaminase of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients) | 14 days |
| Albumin | comparing Albumin of baseline laboratory data with end-of-treatment labs | 14 days |
| Alkaline Phosphatase | comparing the Alkaline Phosphatase of baseline laboratory data with end-of-treatment labs | 14 days |
| Lactate Dehydrogenase | A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by comparing the serum Lactate Dehydrogenase level of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients). | 14 days |
| C-Reactive Protein | A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by comparing the serum C-Reactive Protein level of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients). | 14 days |
| Mid-turbinate SARS CoV-2 Viral Load | A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by changes in the SARS CoV-2 viral loads among mid-turbinate nasal swabs taken on days 0, 4, 7 and 14. | 14 days |
| Adj. EGFR | A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by comparing the Adj. EGFR of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients). | 14 days |
| APTT | A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by comparing the APTT of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients). | 14 days |
| INR | A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by comparing the INR of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients). The INR is a result of a blood test that measures how long it takes for blood to clot, also known as the prothrombin time (PT). The INR is calculated by comparing the PT to the mean normal prothrombin time (MNPT). | 14 days |
| ESR | A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by comparing the ESR of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients). | 14 days |
| Symptom Count | Symptom severity was assessed via a daily questionnaire across Days 0-14, where participants rated their symptoms on a scale of 0 (none or absent) to 3 (severe). A composite measure was created for each day, based on the 12 symptoms most commonly associated with COVID-19 (fever, fatigue, muscle aches, shortness of breath, shortness of breath upon exertion, cough, sore throat, stuffy nose, runny nose, loss of taste, loss of smell, headache), and counting the total number of symptoms present. scores of 1 or more were considered to be present. | 14 days |
| Symptom Severities | Symptom severity was assessed via a daily questionnaire across Days 0-14, where participants rated their symptoms on a scale of 0 (none or absent) to 3 (severe). A composite measure was created for each day, based on the 12 symptoms most commonly associated with COVID-19 (fever, fatigue, muscle aches, shortness of breath, shortness of breath upon exertion, cough, sore throat, stuffy nose, runny nose, loss of taste, loss of smell, headache), and summing the total symptom severities. Higher symptom severities indicates a worse outcome. The minimum and maximum were: 0 to 36, respectively. | 14 days |
| San Diego |
| California |
| 92093 |
| United States |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Total Protein Normal | Count of Participants | Participants |
|
| Albumin Normal | Count of Participants | Participants |
|
| Alkaline Phosphatase Normal | Count of Participants | Participants |
|
| AST Normal | aspartate aminotransferase | Count of Participants | Participants |
|
| ALT Normal | alanine transaminase | Count of Participants | Participants |
|
| Total Bilirubin Normal | Count of Participants | Participants |
|
| eGFR Normal | estimated glomerular filtration rate | Count of Participants | Participants |
|
| Prothrombin Time Normal | Count of Participants | Participants |
|
| APTT Normal | Activated partial thromboplastin time | Count of Participants | Participants |
|
| ESR Normal | Count of Participants | Participants |
|
| CRP Normal | C-Reactive Protein | Count of Participants | Participants |
|
| LDH Normal | Lactate dehydrogenase | Count of Participants | Participants |
|
|
|
| Primary | Albumin Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | Posted | Number | percentage of participants | 14 days |
|
|
|
|
| Primary | Alkaline Phosphatase Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | Chi-square statistic could not be computed because all participants who were normal at baseline were also normal at day 14. | Posted | Number | percentage of participants | 14 days |
|
|
|
| Primary | AST Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | Chi-square statistic could not be computed because all participants who were normal at baseline were also normal at day 14. | Posted | Number | percentage of participants | 14 days |
|
|
|
| Primary | ALT Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | Posted | Number | percentage of participants | 14 days |
|
|
|
|
| Primary | Bilirubin Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | Chi-square statistic could not be computed because all participants who were normal at baseline were also normal at day 14. | Posted | Number | percentage of participants | 14 days |
|
|
|
| Primary | Adj. EGFR Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | Posted | Number | percentage of participants | 14 days |
|
|
|
|
| Primary | Prothrombin Time Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | Posted | Number | percentage of participants | 14 days |
|
|
|
|
| Primary | APTT Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | Posted | Number | percentage of participants | 14 days |
|
|
|
|
| Primary | ESR Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | Posted | Number | percentage of participants | 14 days |
|
|
|
|
| Primary | CRP Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | Chi-square statistic could not be computed because all participants who were normal at baseline were also normal at day 14. | Posted | Number | percentage of participants | 14 days |
|
|
|
| Primary | LDH Normal to Abnormal Transition | We examined participants who were normal at Baseline (Day 1). The Normal to Abnormal proportion reflects the proportion of participants with normal values at Day 1 that became abnormal at Day 14 relative to all participants with normal values at baseline. | Posted | Number | percentage of participants | 14 days |
|
|
|
|
| Secondary | Total Bilirubin | comparison of the Total Bilirubin of baseline laboratory data with end-of-treatment labs | Posted | Mean | Standard Deviation | mg/dL | 14 days |
|
|
|
|
| Secondary | Prothrombin Time | comparison of the prothrombin time of baseline laboratory data with end-of-treatment labs | Posted | Mean | Standard Deviation | sec | 14 days |
|
|
|
|
| Secondary | Aspartate Aminotransferase (AST) | Comparison of the aspartate transaminase of baseline laboratory data with end-of-treatment labs | Posted | Mean | Standard Deviation | U/L | 14 days |
|
|
|
|
| Secondary | Alanine Transaminase (ALT) | The safety of the study medication will also assessed by a comparison of the alanine transaminase of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients) | Posted | Mean | Standard Deviation | U/L | 14 days |
|
|
|
|
| Secondary | Albumin | comparing Albumin of baseline laboratory data with end-of-treatment labs | Posted | Mean | Standard Deviation | U/L | 14 days |
|
|
|
|
| Secondary | Alkaline Phosphatase | comparing the Alkaline Phosphatase of baseline laboratory data with end-of-treatment labs | Posted | Mean | Standard Deviation | U/L | 14 days |
|
|
|
|
| Secondary | Lactate Dehydrogenase | A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by comparing the serum Lactate Dehydrogenase level of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients). | Posted | Mean | Standard Deviation | U/L | 14 days |
|
|
|
|
| Secondary | C-Reactive Protein | A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by comparing the serum C-Reactive Protein level of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients). | Posted | Mean | Standard Deviation | mg/dL | 14 days |
|
|
|
|
| Secondary | Mid-turbinate SARS CoV-2 Viral Load | A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by changes in the SARS CoV-2 viral loads among mid-turbinate nasal swabs taken on days 0, 4, 7 and 14. | Posted | Mean | Standard Deviation | copies per mL | 14 days |
|
|
|
|
| Secondary | Adj. EGFR | A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by comparing the Adj. EGFR of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients). | Posted | Mean | Standard Deviation | mL/min | 14 days |
|
|
|
|
| Secondary | APTT | A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by comparing the APTT of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients). | Posted | Mean | Standard Deviation | sec | 14 days |
|
|
|
|
| Secondary | INR | A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by comparing the INR of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients). The INR is a result of a blood test that measures how long it takes for blood to clot, also known as the prothrombin time (PT). The INR is calculated by comparing the PT to the mean normal prothrombin time (MNPT). | Posted | Mean | Standard Deviation | ratio | 14 days |
|
|
|
|
| Secondary | ESR | A secondary exploratory objective will be to evaluate COVID-19 severity among subjects in each of the two medication arms, compared with placebo, as ascertained by comparing the ESR of baseline laboratory data with end-of-treatment labs or on hospital admission labs (for hospitalized patients). | Posted | Mean | Standard Deviation | mm/hr | 14 days |
|
|
|
|
| Secondary | Symptom Count | Symptom severity was assessed via a daily questionnaire across Days 0-14, where participants rated their symptoms on a scale of 0 (none or absent) to 3 (severe). A composite measure was created for each day, based on the 12 symptoms most commonly associated with COVID-19 (fever, fatigue, muscle aches, shortness of breath, shortness of breath upon exertion, cough, sore throat, stuffy nose, runny nose, loss of taste, loss of smell, headache), and counting the total number of symptoms present. scores of 1 or more were considered to be present. | Posted | Mean | Standard Deviation | Total Number of Symptoms | 14 days |
|
|
|
|
| Secondary | Symptom Severities | Symptom severity was assessed via a daily questionnaire across Days 0-14, where participants rated their symptoms on a scale of 0 (none or absent) to 3 (severe). A composite measure was created for each day, based on the 12 symptoms most commonly associated with COVID-19 (fever, fatigue, muscle aches, shortness of breath, shortness of breath upon exertion, cough, sore throat, stuffy nose, runny nose, loss of taste, loss of smell, headache), and summing the total symptom severities. Higher symptom severities indicates a worse outcome. The minimum and maximum were: 0 to 36, respectively. | Posted | Mean | Standard Deviation | units on a scale | 14 days |
|
|
|
|
| 0 |
| 26 |
| 0 |
| 26 |
| 1 |
| 26 |
| EG001 | Placebo | Organic brown rice FoTv: 8 capsules three times a day for 14 consecutive days. | 0 | 24 | 0 | 24 | 2 | 24 |
|
| High Glucose | Metabolism and nutrition disorders | Non-systematic Assessment | high glulcose level reported in a participant who had diabetes |
|
Not provided
Not provided
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| Day 14 |
|
| Day 2 |
|
| Day 3 |
|
| Day 4 |
|
| Day 5 |
|
| Day 6 |
|
| Day 7 |
|
| Day 8 |
|
| Day 9 |
|
| Day 10 |
|
| Day 11 |
|
| Day 12 |
|
| Day 13 |
|
| Day 14 |
|
| Day 2 |
|
| Day 3 |
|
| Day 4 |
|
| Day 5 |
|
| Day 6 |
|
| Day 7 |
|
| Day 8 |
|
| Day 9 |
|
| Day 10 |
|
| Day 11 |
|
| Day 12 |
|
| Day 13 |
|
| Day 14 |
|